Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

N/A

3(75.0%)

Phase 4

1(25.0%)

4Total

N/A(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06625112Recruiting

A Multicentric European Study to Promote Clinical Trial Readiness for STXBP1-related Disorders

Role: collaborator

NCT05933876Recruiting

The Impact of Radiotherapy on Oligometastatic Cancer

Role: collaborator

NCT06312969Not ApplicableRecruiting

Technological Gaming in Cancer Survivors (WINNERS)

Role: collaborator

NCT05232630Phase 4Recruiting

Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes

Role: lead

NCT04833322Not ApplicableUnknown

Galactose Supplementation for the Treatment of MOGHE

Role: lead

NCT04055363Not ApplicableCompleted

Human Milk Oligosaccharides (HMOs) Post-market Study on Infants

Role: collaborator

All 6 trials loaded